Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Antibiotic - fixed-extended-duration

Phase 3

Antibiotic - fixed-extended-duration is one of 2 therapeutic programs targeting Intra-abdominal Infection. It is currently in Phase 3.

1

Indications

1

Total Trials

1

Active Trials

1

Competitors

Pipeline

Status by Indication[2][1]

Indication

Intra-Abdominal InfectionActive, not recruiting

Intra-Abdominal InfectionPhase 3

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Intra-Abdominal Infection

#DrugCompanyPhaseTrials

Antibiotic - fixed-extended-duration

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Intra-abdominal Infection1 trial

The EXTEND Trial: Fixed-extended-duration Antibiotics (28 Days) Compared to Standard Care Antibiotic Durations in Adult Patients With Complicated Intra-abdominal Infection and Their Impact on Treatment Failure

Active, not recruiting·SSarah Cockayne·Phase 3·NCT05148702·1,166 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Antibiotic - fixed-extended-duration. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Antibiotic - fixed-extended-duration. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Lydia Flett company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: LLydia Flett

Related News